Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an impressive resume already, but it's just getting started. It's currently in the ...

CRISPR-Cas9 has long been likened to a kind of genetic scissors, thanks to its ability to snip out any desired section of DNA with elegant precision. But it turns out that CRISPR systems have more ...

It acts as a sort of molecular fumigator to battle phages and plasmids. CRISPR-Cas9 has long been likened to a kind of genetic scissors, thanks to its ability to snip out any desired section of ...

CRISPR/Cas9 is a gene editing tool that has revolutionized biomedical research and led to the first FDA-approved CRISPR-based gene therapy. However, until now, the precise mechanism of exactly how ...

Using CRISPR editing techniques, researchers created new “mutant” tomatoes that are as large as modern varieties while retaining a sweeter, more enjoyable taste. And all it took was ...

CRISPR Therapeutics' early-stage pipeline output is likely to increase soon. Eventually, the company will have to ink new collaboration deals or raise fresh capital. A high degree of regulatory ...

Understanding these underlying mechanisms of how CRISPR and Cas9 operate could lead to more effective forms of gene editing technology, including the potential to deliver the therapy directly into ...

Jennifer Doudna, the co-developer of CRISPR, says there’s a “coming ... published their landmark paper on the technique in Science 12 years ago, demonstrating that a bacterial immune system ...

Coming less than a decade after its launch, the studies emerging from the global project are a major achievement. Funders should sign up for the long haul.

CRISPR Therapeutics AG (NASDAQ:CRSP) investors still suffer from the stock's tepid momentum. It has also underperformed its healthcare sector (XLV) and biotechnology peers (XBI). As a result, the ...

Sanwen Huang, the director general of the agricultural genomics institute at the Chinese Academy of Agricultural Science ... They used CRISPR-Cas9 gene-editing technology to “knock out ...